Key result
Colchicine and cytochalasin B show ADP-induced fibrinogen binding links to platelet aggregability, not shape change.
In vitro studies demonstrate that fibrinogen binding to platelets is associated with aggregability rather than platelet shape change.
Answers are grounded in this paper and cite their sources.
Should not alter antiplatelet regimens; leaves open mechanistic distinctions in platelet activation for targeted study.
ADP causes human, aspirin-treated, gel-filtered platelets to change from their native discoid shape to spiny spheres with pseudopods, bind 125I-labeled fibrinogen, and aggregate if shaken with sufficient fibrinogen. After destruction of the added ADP with the enzyme apyrase, the platelets revert to a disc shape and lose much of their bound fibrinogen. Colchicine (208 muM or 83 microgram/ml) added to ADP-treated platelets before apyrase prevented restoration of the discoid shape but not the loss of bound fibrinogen. It did not inhibit ADP-induced shape change, aggregation, or fibrinogen binding. Cytochalasin B (0.02--0.2 muM or 0.01--0.10 microgram/ml) prevented ADP-induced shape change but not ADP-induced fibrinogen binding or aggregation. Thus, these findings support earlier studies with thrombasthenic and EDTA-treated platelets and with normal platelets at low pH, or in the presence of EDTA to indicate that fibrinogen binding is associated with aggregability but not with platelet shape.
No takes yet. Share an insight, caveat, or question.
Peerschke et al. (1980) studied this question. Colchicine and Cytochalasin B was evaluated on Platelet shape change, fibrinogen binding, and aggregation. Colchicine and cytochalasin B demonstrated that ADP-induced fibrinogen binding in human platelets is associated with aggregability but not with platelet shape change.
Synapse has enriched 10 related papers. Consider them for comparative context: